- Home
- EBS vs CMPX Comparison
EBS vs CMPX Comparison
Compare EBS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- CMPX
- Stock Information
- Founded
- EBS 1998
- CMPX 2014
- Country
- EBS United States
- CMPX United States
- Employees
- EBS N/A
- CMPX N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- CMPX Health Care
- Exchange
- EBS Nasdaq
- CMPX Nasdaq
- Market Cap
- EBS 393.9M
- CMPX 229.5M
- IPO Year
- EBS 2006
- CMPX N/A
- Fundamental
- Price
- EBS $6.38
- CMPX $1.78
- Analyst Decision
- EBS Strong Buy
- CMPX Strong Buy
- Analyst Count
- EBS 3
- CMPX 8
- Target Price
- EBS $14.33
- CMPX $13.57
- AVG Volume (30 Days)
- EBS 1.1M
- CMPX 739.7K
- Earning Date
- EBS 05-07-2025
- CMPX 05-08-2025
- Dividend Yield
- EBS N/A
- CMPX N/A
- EPS Growth
- EBS N/A
- CMPX N/A
- EPS
- EBS N/A
- CMPX N/A
- Revenue
- EBS $965,400,000.00
- CMPX $850,000.00
- Revenue This Year
- EBS N/A
- CMPX $47.65
- Revenue Next Year
- EBS $19.88
- CMPX $2,622.79
- P/E Ratio
- EBS N/A
- CMPX N/A
- Revenue Growth
- EBS N/A
- CMPX N/A
- 52 Week Low
- EBS $4.02
- CMPX $0.77
- 52 Week High
- EBS $15.10
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- EBS 65.88
- CMPX 44.50
- Support Level
- EBS $4.71
- CMPX $1.79
- Resistance Level
- EBS $5.70
- CMPX $1.95
- Average True Range (ATR)
- EBS 0.38
- CMPX 0.14
- MACD
- EBS 0.13
- CMPX 0.01
- Stochastic Oscillator
- EBS 85.77
- CMPX 21.15
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.